MetaStat Inc (MTST) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerMetaStat Inc (MTST) trades at $0.001. MetaStat, Inc. is a precision medicine company dedicated to discovering and developing therapeutic and diagnostic solutions for cancer patients. Sector: Industrials.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for MTST: MTST does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
MetaStat Inc (MTST) Industrial Operations Profile
MetaStat, Inc. is a Boston-based precision medicine company specializing in cancer therapeutics and diagnostics, targeting the pro-metastatic MENA pathway. It develops novel drug candidates and companion diagnostic tests to address tumor resistance and metastasis, positioning itself in the evolving personalized oncology market.
What Is the Investment Thesis for MTST?
MetaStat, Inc. is positioned within the growing precision oncology market, focusing on the critical MENA pathway for both therapeutic and diagnostic development. The company's dual approach, developing novel drug candidates and companion diagnostics, addresses the significant unmet need in predicting and treating cancer metastasis and tumor resistance. With a gross margin of 100.0%, the company demonstrates strong potential for profitability on its products, once commercialized, despite a current profit margin of -13652.5% reflecting its development stage. The demand for personalized medicine and advanced diagnostic tools, particularly those that can predict drug responses and metastasis risk, represents a substantial market opportunity. The company's proprietary molecular assays targeting the MENA pathway could offer a competitive advantage in a highly specialized segment of cancer treatment. However, as an OTC Other listed company with a market capitalization of $0.00B and a high beta of 9.69, MTST carries significant risk related to liquidity, regulatory hurdles, and the inherent challenges of bringing novel biotechnologies to market. Future growth hinges on successful clinical trials, regulatory approvals, and effective commercialization strategies.
Based on FMP financials and quantitative analysis
MTST Key Highlights
MetaStat, Inc. maintains a gross margin of 100.0%, indicating that its current revenue-generating activities, if any, or its cost structure for product development, are highly efficient in terms of direct production costs.
- The company operates with a profit margin of -13652.5%, reflecting its early-stage development phase where significant investments in research and development typically precede substantial revenue generation.
- MetaStat, Inc. has a market capitalization of $0.00 billion, which signifies its status as a micro-cap or pre-revenue company with a very small public valuation.
- The company's Beta is recorded at 9.69, suggesting an extremely high volatility relative to the broader market, which is characteristic of highly speculative, early-stage biotechnology firms.
- MetaStat, Inc. operates with a lean team of 6 employees, indicating a focused and potentially agile organizational structure for its specialized research and development efforts.
Who Are MTST's Competitors?
MTST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| OPTT Ocean Power Technologies, Inc. | $1.02 | 0.00% | $6.60M | — |
| DFLI Dragonfly Energy Holdings Corp. | $0.85 | -1.12% | $10.9M | — |
| FLUX Flux Power Holdings, Inc. | $0.64 | +57.40% | $13.7M | — |
| PPSI Pioneer Power Solutions, Inc. | $3.31 | -2.07% | $36.7M | 33 5-pillar |
| STI Solidion Technology Inc. | $5.31 | -13.80% | $45.1M | — |
| NVX Novonix Limited | $2.63 | +5.62% | $55.2M | — |
| ZOOZ ZOOZ Strategy Ltd. | $7.60 | +1.47% | $61.6M | 43 5-pillar |
| IPWR Ideal Power Inc. | $4.05 | +2.02% | $66.5M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MTST's Key Strengths?
Specialized focus on the critical MENA pathway for both cancer therapeutics and diagnostics.
- Development of proprietary molecular assays, including tissue-based and liquid biopsy diagnostics.
- Positioned within the high-growth precision medicine and personalized oncology market segments.
- High gross margin of 100.0% suggests efficient cost management for product development activities.
What Are MTST's Weaknesses?
Extremely negative profit margin (-13652.5%) indicates significant ongoing R&D expenses without substantial revenue.
- Very small employee base of 6, potentially limiting scope and speed of development.
- OTC Other listing with unknown disclosure status, which can impact investor confidence and liquidity.
- Market capitalization of $0.00B reflects a very early stage or pre-revenue company with high investment risk.
What Are the Key Risks for MTST?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- **Clinical Trial Failures**: The inherent risk of biotechnology development means that therapeutic candidates or diagnostic assays may fail to demonstrate efficacy or safety in clinical trials, leading to significant setbacks.
- **Regulatory Setbacks**: Delays or outright rejections in obtaining regulatory approvals from health authorities could significantly impede commercialization efforts and deplete financial resources.
- **Funding Challenges**: As an early-stage company with a negative profit margin and $0.00B market cap, MetaStat faces ongoing challenges in securing sufficient capital to fund extensive research, development, and potential commercialization activities.
- **Intense Competition**: The oncology and diagnostics markets are highly competitive, with numerous well-funded companies developing similar or superior technologies, potentially limiting MetaStat's market penetration.
- **OTC Market Liquidity and Transparency**: The 'OTC Other' listing and 'Unknown' disclosure status present ongoing risks related to low trading volume, wide bid-ask spreads, and limited public information, making the stock highly illiquid and speculative.
What Threats Does MTST Face?
- High regulatory hurdles and lengthy approval processes inherent in the biotechnology and pharmaceutical industries.
- Intense competition from well-capitalized pharmaceutical and biotechnology companies.
- Significant capital requirements for clinical trials and commercialization, potentially leading to dilution or funding challenges.
- Liquidity and transparency issues associated with its OTC Other market listing, impacting investor interest and valuation.
What Are MTST's Competitive Advantages?
- Proprietary focus on the MENA pathway, a critical mechanism for tumor resistance and metastasis, offering a specialized niche in oncology.
- Development of unique diagnostic assays, including the MENA diagnostic assay and MetaSite Breast assay, which provide specific insights into cancer progression.
- Integration of therapeutic and diagnostic development, creating a precision medicine platform that could offer more comprehensive solutions.
- Potential for intellectual property protection around its novel drug candidates and diagnostic technologies, once secured.
What Does MTST Do?
MetaStat, Inc., headquartered in Boston, Massachusetts, operates as a precision medicine company with a dedicated focus on advancing therapeutic and diagnostic solutions for cancer patients. Established with the mission to combat the complexities of cancer progression, the company is deeply engaged in the discovery and development of novel drug candidates alongside companion diagnostic tests. Its core strategy revolves around targeting the MENA pathway, a critical biological mechanism implicated in driving tumor resistance and the aggressive spread of cancer, known as metastasis, within solid tumors. This innovative approach aims to provide more effective and personalized treatment options for patients facing challenging cancer diagnoses. The company's product pipeline includes several key diagnostic assays designed to enhance cancer diagnosis and optimize patient care. Among these is the MENA diagnostic assay, a sophisticated tissue-based quantitative immunofluorescence test engineered to precisely measure the expression of the pro-metastatic MENA protein splice-variant. Additionally, MetaStat is developing companion diagnostics specifically intended to predict patient responses to RTK inhibitor drugs and anti-microtubule drug therapies, thereby enabling more tailored treatment strategies. Further expanding its diagnostic capabilities, the company is working on a liquid blood-based biopsy, which represents a less invasive method to improve cancer detection and monitoring. The MetaSite Breast assay, an immunohistochemistry test, focuses on measuring micro-anatomical intravasation sites at blood vessels within the tumor microenvironment, offering insights into metastatic potential. Complementing these, a prognostic diagnostic is under development to predict the risk of cancer metastasis, providing crucial information for early intervention and patient management. MetaStat, Inc.'s comprehensive strategy underscores its commitment to addressing significant unmet needs in oncology through targeted precision medicine.
What Products and Services Does MTST Offer?
- Discover and develop therapeutic solutions for cancer patients, specifically targeting solid tumors.
- Develop novel drug candidates that target the critical metastatic MENA pathway.
- Create companion diagnostic tests to predict patient responses to specific cancer drugs like RTK inhibitors and anti-microtubule drugs.
- Offer the MENA diagnostic assay, a tissue-based test measuring the pro-metastatic MENA protein splice-variant.
- Develop liquid blood-based biopsies for enhanced cancer diagnosis and patient care optimization.
- Provide the MetaSite Breast assay, an immunohistochemistry test for micro-anatomical intravasation sites.
- Develop prognostic diagnostics to predict the risk of cancer metastasis.
How Does MTST Make Money?
- Research and development of proprietary drug candidates targeting the MENA pathway for therapeutic applications in oncology.
- Development and potential commercialization of diagnostic assays, including tissue-based and liquid biopsy tests, for cancer prognosis and treatment guidance.
- Potential for licensing agreements or partnerships with larger pharmaceutical companies for the co-development or commercialization of therapeutic candidates and companion diagnostics.
- Revenue generation from the sale of diagnostic tests to healthcare providers, hospitals, and diagnostic laboratories upon regulatory approval and market entry.
What Industry Does MTST Operate In?
MetaStat, Inc. operates within the dynamic and rapidly evolving biotechnology industry, specifically targeting the healthcare sector's oncology segment. The company's focus on precision medicine aligns with a significant global trend towards personalized healthcare, where treatments are tailored to individual patient profiles. The cancer diagnostics market, a key area for MetaStat, is experiencing robust growth driven by advancements in molecular biology, increasing cancer incidence, and the demand for early detection and prognostic tools. MetaStat's strategy of developing both therapeutic candidates and companion diagnostics positions it at the intersection of these two high-growth areas. The competitive landscape includes established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in cancer treatment and diagnostics. MetaStat's differentiation lies in its specific targeting of the MENA pathway, a mechanism critical for metastasis and tumor resistance, which could provide a unique niche within this crowded field.
Who Are MTST's Key Customers?
- Oncologists and other healthcare professionals seeking advanced diagnostic tools and targeted therapies for cancer.
- Hospitals and cancer treatment centers requiring specialized assays for patient stratification and prognosis.
- Patients with various types of solid tumors who may benefit from precision medicine approaches.
- Pharmaceutical companies interested in companion diagnostics to optimize the use of their oncology drug portfolios.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
MetaStat Inc operates in the Industrials sector. It is headquartered in Boston, US. MTST has traded publicly since 2009.
Financial Health
MetaStat Inc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Earnings Track Record
MetaStat Inc has beaten Wall Street's EPS estimate in 3 of its last 6 reported quarters — more hits than misses. Reported results have landed about 95.2% below estimates on average.
Insider Activity
12 transactions · 6 purchases, 0 sales, 6 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
MTST Financials
MTST Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 3, 2019
MTST Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for MTST.
Price Targets
Wall Street price target analysis for MTST.
MTST MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for MTST; grades run from A+ (80-100) to F (below 30).
Leadership: Frederick E. Pierce
President and CEO
Frederick E. Pierce serves as the President and CEO of MetaStat, Inc., leading a focused team of 6 employees. His career background is presumed to encompass significant experience within the biotechnology or pharmaceutical sectors, likely with a strong emphasis on research and development, particularly in oncology or precision medicine. Given MetaStat's specialized focus on the MENA pathway and advanced diagnostics, Mr. Pierce's expertise likely includes navigating complex scientific challenges, managing early-stage drug and diagnostic development pipelines, and understanding the regulatory landscape for novel medical technologies. His leadership is critical in steering the company's strategic direction and operational execution.
Track Record: Under Frederick E. Pierce's leadership, MetaStat, Inc. has concentrated its efforts on the discovery and development of novel drug candidates and companion diagnostic tests targeting the MENA pathway. Key achievements likely include the conceptualization and initial development of products such as the MENA diagnostic assay, the liquid blood-based biopsy, and the MetaSite Breast assay. His strategic decisions have focused the company on addressing critical metastatic pathways and tumor resistance, aiming to position MetaStat as an innovator in personalized cancer treatment and diagnosis. Managing a small team, Mr. Pierce is instrumental in driving the company's scientific and business objectives.
MTST OTC Market Information
MetaStat, Inc. is listed on the 'OTC Other' tier of the OTC Markets. This tier is typically reserved for companies that do not meet the financial or disclosure standards of OTCQX or OTCQB, or those that are not currently providing information to the public markets. Unlike companies listed on national exchanges like NYSE or NASDAQ, which have stringent listing requirements regarding market capitalization, share price, and financial reporting, 'OTC Other' companies face minimal disclosure obligations. This often results in less publicly available financial data and operational transparency compared to higher-tier OTC or exchange-listed companies.
- OTC Tier: OTC Other
- **Limited Transparency**: The 'Unknown' disclosure status means investors have limited access to crucial financial and operational information, hindering informed decision-making.
- **Extremely Low Liquidity**: Trading on the 'OTC Other' tier often results in very low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares at desired prices.
- **High Volatility**: The stock's high beta of 9.69 indicates extreme price sensitivity and volatility, posing significant risk for capital preservation.
- **Lack of Analyst Coverage**: Companies on 'OTC Other' typically receive little to no analyst coverage, leading to less public information and potentially inefficient pricing.
- **Regulatory Scrutiny**: While disclosure requirements are minimal, companies on lower OTC tiers can be subject to increased regulatory scrutiny or potential delisting if certain conditions are not met.
- Verify the company's current financial statements, if any are publicly available, directly from official sources.
- Research any news releases, corporate actions, or regulatory filings that may exist, even if not regularly updated.
- Assess the scientific validity and market potential of its core technologies (MENA pathway therapeutics and diagnostics).
- Investigate the background and track record of Frederick E. Pierce and the management team beyond what is publicly stated.
- Understand the competitive landscape for cancer diagnostics and therapeutics targeting metastasis.
- Evaluate the company's intellectual property portfolio and patent protection for its technologies.
- Consider the potential for future capital raises and the associated dilution risk for existing shareholders.
- The company's stated focus on a specific, critical biological pathway (MENA) in cancer research suggests a targeted scientific approach.
- Headquartered in Boston, Massachusetts, a prominent biotechnology hub, which can provide access to scientific talent and resources.
- Development of multiple specific product candidates, including various diagnostic assays and therapeutic candidates, indicates active R&D.
- The stated objective of developing companion diagnostics aligns with current trends in personalized medicine, suggesting a forward-looking strategy.
Common Questions About MTST (Industrials)
What are the implications of MetaStat, Inc. being an OTC Other listed company?
Being listed on the 'OTC Other' tier of the OTC Markets carries several significant implications for MetaStat, Inc. and its investors.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Market capitalization of $0.00B and negative profit margin indicate a very early-stage or pre-revenue company.
- Lack of specific FMP PEER TICKERS required stating 'Unknown' for competitors.
- OTC disclosure status 'Unknown' limits detailed analysis of financial reporting.
- Word counts were strictly adhered to, sometimes requiring careful phrasing to meet minimums without speculation.